News Tesla Scrutinized by U.S. Agency Over Model 3 Safety Claims The U.S. National Highway Traffic Safety Administration sent Tesla Inc.’s Elon Musk a cease-and-desist letter last year regarding Model 3... Read More
News Novartis Drug Data Allegations Revive Questions Over Ethics Concern over Novartis AG’s corporate culture returned to the spotlight after U.S. regulators said the Swiss drugmaker delayed disclosing manipulation... Read More
News CRU Group, RT Speciality, Lombardi Associates Make Appointments CRU Group Hires CEO for US Claims CRU Group has appointed David Repinski as chief executive officer of CRU USA,... Read More
News Opioid Distributors Propose $10 Billion to End State Claims McKesson Corp., Cardinal Health Inc. and AmerisourceBergen Corp. have proposed paying $10 billion to settle claims they helped to fuel... Read More
News Arizona Asks for US Supreme Court Involvement in Opioid Case PHOENIX — Arizona’s attorney general on Wednesday asked the U.S. Supreme Court to force the Sackler family, which owns OxyContin-maker... Read More
Southeast News Enbridge to Keep Kentucky Gas Pipe Shut for at Least a Week After Blast Canadian energy company Enbridge Inc said the section of its Texas Eastern pipeline in Kentucky that exploded on Thursday, killing... Read More
News Power and Tech Giants Fight Over Airwaves Space in the U.S. As tropical storm Barry roared ashore in Louisiana last month, Entergy Corp. monitored the electric grid using airwaves that have... Read More
News L’Oreal Fights California Startup Over Secret to Protecting Hair L’Oreal SA made its name with an innovative hair-dyeing technology more than a century ago. Now the world’s largest beauty... Read More
East News NJ Transit Withholds Braking-Project Costs as ‘Trade Secret’ New Jersey Transit is withholding the growing cost of one of its biggest-ever capital projects, an emergency rail-braking system ordered... Read More
News Mallinckrodt Puts Off Planned Generics Spinoff Amid Opioid Cases Mallinckrodt Plc said it would suspend the spinoff of its specialty-generics business as it grapples with a wave of lawsuits... Read More